Yunnan Baiyao Group Stock (CNE100000G78): Healthcare valuation check for Shenzhen-listed traditional medicine player

Yunnan Baiyao Group shares trade around CNY 50 on the Shenzhen Stock Exchange, putting the traditional Chinese medicine specialist in focus for a fresh look at fundamentals, valuation multiples and its role in China healthcare benchmarks.

Responsible: ad hoc news Markets & Valuation Desk. Reviewed prior to publication on June 12, 2026 at 6:29 PM ET. Details in the imprint.

Yunnan Baiyao Group, a well-known traditional Chinese medicine and healthcare products manufacturer, is again drawing attention as investors reassess valuations across the China healthcare space. Recent pricing data for Yunnan Baiyao Group shows the shares trading around CNY 50 on the Shenzhen Stock Exchange, with one snapshot placing the stock at roughly CNY 50.60 per share, highlighting a relatively stable performance in the context of modest day-to-day moves in June 2026. While the stock is not listed on a major U.S. exchange, it features in several China-focused healthcare indices and funds, which makes it indirectly relevant for U.S. investors accessing emerging markets through ETFs. Against a backdrop of sector-wide repricing in Chinese pharmaceuticals and medical products, Yunnan Baiyao Group is a candidate for a closer look at fundamentals, competitive positioning and valuation.

How Yunnan Baiyao Group fits into China healthcare valuations

On the Chinese A-share market, Yunnan Baiyao Group is recognized as a mid-to-large capitalization name within the healthcare complex, and it appears in the holdings of China healthcare and broader emerging markets equity products. For example, it is listed as one of the top holdings in the China Universal CSI Health Care Index ETF, under the Shenzhen ticker 000538, alongside other pharmaceutical and medical names such as Zhejiang Nhu and Huadong Medicine. This index inclusion signals that index providers view the company as a meaningful constituent within China’s domestic healthcare universe, which in turn means that flows into and out of related ETFs can influence trading volumes and liquidity in the stock.

From a sector classification perspective, Yunnan Baiyao Group is generally placed in the pharmaceuticals and healthcare products industry, with exposure that spans traditional Chinese medicine formulations, over-the-counter products and consumer health items. The company’s flagship brand Yunnan Baiyao is widely recognized for trauma and bleeding remedies, and its formulas have been commercialized in capsule, powder and topical formats for human and veterinary use. This brand heritage gives the group a differentiated product portfolio compared with many generic-focused pharmaceutical manufacturers, adding a consumer brand angle to the investment case and influencing how markets view its pricing power and margin potential.

The valuation context for Yunnan Baiyao Group is closely tied to the broader performance of China healthcare and emerging markets equity benchmarks. Many diversified emerging market ETFs hold baskets of large and mid-cap Chinese names, including healthcare companies, with factor-based products such as the VanEck MSCI Multifactor Emerging Markets Equity ETF illustrating how portfolio construction can tilt toward quality, value or momentum characteristics among holdings. While fund documentation often does not enumerate Yunnan Baiyao Group individually, the presence of Chinese healthcare peers in these portfolios underscores that investor sentiment toward the sector is influenced by macro factors like interest rates, regulatory shifts and domestic demand for healthcare services.

For Yunnan Baiyao Group specifically, investors tend to look at standard valuation metrics used for pharmaceuticals and consumer health businesses, including price-to-earnings (P/E) ratios, price-to-book (P/B) ratios and enterprise value to EBITDA. Given the company’s established brand and entrenched position in traditional Chinese medicine, the market may assign it a premium relative to smaller, less diversified herbal remedy firms, particularly when its products have long-standing consumer recognition and export potential. At the same time, the stock’s behavior around the CNY 50 level in June 2026 reflects a balance between growth expectations and perceived regulatory or macroeconomic risks within China’s healthcare sector.

Another element of the valuation picture is the company’s integration into consumer health and lifestyle trends. Yunnan Baiyao products show up not just in pharmacies but also in specialized herbal and wellness outlets, and they are increasingly referenced in Western consumer channels where traditional Chinese medicine is discussed for both human and pet applications. This broader recognition can support revenue diversification and help defend margins if domestic reimbursement policies for traditional remedies tighten, although it also introduces competition from both local and international brands making similar claims in the herbal and natural remedies space.

At the portfolio level, Yunnan Baiyao Group’s presence in sector and broad-market indices means its valuation is partially shaped by passive flows, which do not necessarily discriminate based on short-term earnings revisions or product news. When healthcare indices gain or lose favor among global investors, larger constituents like Yunnan Baiyao Group can see their trading volumes adjust accordingly, even without major company-specific catalysts. This index-linked dynamic reinforces the importance of monitoring fund flow data and ETF positioning when assessing how the market might re-rate the stock over time.

For now, the stock’s trading range around the low CNY 50s provides a reference point for comparing Yunnan Baiyao Group’s market capitalization with peers of similar size and sector exposure in China’s domestic market. Investors watching the stock can juxtapose that market price against the company’s role as a top holding in healthcare indices, its branded traditional medicine portfolio and its potential to benefit from long-term growth in healthcare demand across China’s aging population. Overall, the valuation debate around Yunnan Baiyao Group centers on how much of its brand strength and sector positioning is already reflected in the share price versus the uncertainties that still surround regulatory developments and macro conditions in China.

In summary, Yunnan Baiyao Group is currently positioned as a significant China healthcare name with a stable trading level near CNY 50, index inclusion in healthcare benchmarks and a distinctive portfolio built around traditional Chinese medicine and consumer health products. The stock offers exposure to both the pharmaceutical and wellness segments of China’s economy, but its valuation will remain sensitive to sector-wide sentiment, policy changes and global investor appetite for emerging markets, rather than to any one single short-term catalyst.

Yunnan Baiyao Group at a glance

• Name: Yunnan Baiyao Group Co., Ltd.
• Industry: Pharmaceuticals and healthcare products with a focus on traditional Chinese medicine and consumer health items
• Headquarters: Kunming, Yunnan Province, China
• Core markets: Mainland China and selected international markets for traditional Chinese medicine and over-the-counter healthcare products
• Revenue drivers: Branded Yunnan Baiyao trauma and bleeding remedies, traditional Chinese medicine formulations, over-the-counter consumer health products, and related healthcare items
• Listing: Shenzhen Stock Exchange, A-share listing under ticker 000538; included in China healthcare and broader China equity indices and ETFs
• Trading currency: Chinese yuan (CNY), with the stock recently quoted around CNY 50.60 per share in June 2026

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.